Yogish Kudva, MBBS
Enriched profileProfessor of Medicine, Mayo Clinic College of Medicine and Science · Mayo Clinic
Yogish Kudva is Professor of Medicine, Mayo Clinic College of Medicine and Science at Mayo Clinic. OpenAlex indexes 363 publications with 14,665 citations (h-index 64); ClinicalTrials.gov lists 15 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Endocrinology, Diabetes & Metabolism profiles in the findmyKOL directory.
Data verified 18 Oct 2026
Overview
Updated 18 Oct 2026
Yogish Kudva, MBBS, is Professor of Medicine, Mayo Clinic College of Medicine and Science. The public record shows 363 publications with 14,665 citations (h-index 64), centered on Diabetes Management and Research, Diabetes Management and Education, Diabetes Treatment and Management. It also documents an investigator role on 15 registered clinical trials, industry payments reported by 9 companies, 4 NIH-funded awards (2009–2026).
- Most recent indexed publication: 2026 · JCEM case reports
- Top research focus: Diabetes Management and Research
- 15 registered trials on ClinicalTrials.gov
- Open Payments reporting from 9 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 31 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 163.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- Director
Artificial Pancreas Laboratory, Mayo Clinic
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mayo.edu ↗ - Principal Investigator
NIH-funded artificial pancreas research program
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mayo.edu ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 15 registered studies on ClinicalTrials.gov. The most recent:
- Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes
Sponsor: Insulet Corporation
- PACTAID App in Adults With Type 1 Diabetes to Help Manage Exercise
Sponsor: Mayo Clinic
Industry payments
Updated 18 Oct 2026
9 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Novo Nordisk IncProgram year20255 payments
- VERTEX PHARMACEUTICALS INCORPORATEDProgram year202512 payments
- SANOFI-AVENTIS U.S. LLCProgram year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
72.2%Insulin Analog25.6%Lantus Solostar23%Tresiba Flextouch U-10022%Novolog19%Humalog17%Novolog Flexpen11%Lantus9%Part D<11 patientsGLP-1 receptor agonist21.5%Ozempic52%Mounjaro30%Trulicity18%Part D<11 patients+ 5 more classes in this area
Cardiovascular
18.5%Cholesterol absorption inhibitor10%Ezetimibe100%Part D≥18 patientsStatin8.5%Atorvastatin Calcium70%Rosuvastatin Calcium30%Part D<11 patientsCancer & immunology
5%Calcineurin inhibitor5%Tacrolimus100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 18 Oct 2026
4 NIH research awards on record, funded 2009–2026 per NIH RePORTER. The latest:
- Effects of Sleep Restriction on Glycemic Control and Cardiovascular Risk Mechanisms in Type 1 Diabetes Mellitus
Mayo Clinic Rochester
FY2026$806,199R01HL178855 - Parallel-group randomized controlled trial of Pioglitazone versus empagliflozin for T3cDM: The PEP-DM Trial
Mayo Clinic Rochester
FY2026$318,445R01DK137868
Congress activity
Updated 18 Oct 2026
40 congress contributions (2015–2025) across AACE, ADA, ASH, ENDO per OpenAlex. The most recent:
- 1517-P: Higher Risk of Noncardiovascular Death in a Population-Based Cohort of Type 1 Diabetes
ADA Scientific Sessions
ADA2025Co-authorPoster - 1546-P: Cardiovascular Adverse Events and Mortality in Patients with Immune Checkpoint Inhibitor–Associated Diabetes Mellitus- A 10-Year Follow-up Study
ADA Scientific Sessions
ADA2025Co-authorPoster - 242-OR: Effects of Automated Insulin Delivery (AID) on Impaired Awareness of Hypoglycemia (IAH) in Older Adults with Type 1 Diabetes in the AIDE Study
ADA Scientific Sessions
ADA2025Co-authorOral
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 18 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Simultaneous immune checkpoint blockade-associated diabetes mellitus and thyrotoxicosis.
JCEM case reports
Case Report2026 - Determinants of Cognitive Change Over 1 Year in Older Adults With Type 1 Diabetes.
Diabetes, obesity, and cardiometabolic CARE
Article2026 - A Multicenter Study of an Investigational Extended Wear Insulin Infusion Set in Adults with Type 1 Diabetes.
Diabetes technology & therapeutics
Article2026 - Significant Hyperglycemia in Hospitalized Total Pancreatectomy Patients: Results of a Pilot Prospective Continuous Glucose Monitoring Study.
Diabetes technology & therapeutics
Article2025 - Automated Insulin Delivery in Elderly with Type 1 Diabetes: A Prespecified Analysis of the Extension Phase.
Diabetes technology & therapeutics
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)- 01Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 DiabetesArticle1,023 citations2019
- 02Improvement in Outcomes of Clinical Islet Transplantation: 1999–2010Article725 citations2012
- 03Benign Paragangliomas: Clinical Presentation and Treatment Outcomes in 236 PatientsArticle626 citations2001
- 04
- 05
Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 18 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- Other
mayo.edu/research/faculty/kudva-yogish-c-m-b-b-s/bio-00078171
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayo.edu ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mayoclinic.org ↗
Editorial & leadership roles
journal and society appointments- Board Certified
Endocrinology, Diabetes & Metabolism (American Board of Internal Medicine)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mayoclinic.org ↗ - Board Certified
Internal Medicine (American Board of Internal Medicine)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mayoclinic.org ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mayoclinic.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mayoclinic.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mayoclinic.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
S Rajkumar, MD
Mayo Clinic
Bradley Boeve, MD
Mayo Clinic
Victor Montori, MD
Mayo Clinic
Ayalew Tefferi, MD
Mayo Clinic
Eric Van Cutsem, MD, PhD
University Hospitals Leuven (UZ Leuven)
Josep Tabernero, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Charles Fuchs, MD, MPH
Tubulis GmbH